These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

372 related articles for article (PubMed ID: 23735626)

  • 1. Cryptococcal meningitis: improving access to essential antifungal medicines in resource-poor countries.
    Loyse A; Thangaraj H; Easterbrook P; Ford N; Roy M; Chiller T; Govender N; Harrison TS; Bicanic T
    Lancet Infect Dis; 2013 Jul; 13(7):629-37. PubMed ID: 23735626
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Flucytosine and cryptococcosis: time to urgently address the worldwide accessibility of a 50-year-old antifungal.
    Loyse A; Dromer F; Day J; Lortholary O; Harrison TS
    J Antimicrob Chemother; 2013 Nov; 68(11):2435-44. PubMed ID: 23788479
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Responding to the evidence for improved treatment for cryptococcal meningitis in resource-limited settings.
    Milani B; Ford N
    S Afr Med J; 2012 Mar; 102(4):196-7. PubMed ID: 22464494
    [No Abstract]   [Full Text] [Related]  

  • 4. AMBIsome Therapy Induction OptimisatioN (AMBITION): High Dose AmBisome for Cryptococcal Meningitis Induction Therapy in sub-Saharan Africa: Study Protocol for a Phase 3 Randomised Controlled Non-Inferiority Trial.
    Lawrence DS; Youssouf N; Molloy SF; Alanio A; Alufandika M; Boulware DR; Boyer-Chammard T; Chen T; Dromer F; Hlupeni A; Hope W; Hosseinipour MC; Kanyama C; Lortholary O; Loyse A; Meya DB; Mosepele M; Muzoora C; Mwandumba HC; Ndhlovu CE; Niessen L; Schutz C; Stott KE; Wang D; Lalloo DG; Meintjes G; Jaffar S; Harrison TS; Jarvis JN
    Trials; 2018 Nov; 19(1):649. PubMed ID: 30470259
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group.
    van der Horst CM; Saag MS; Cloud GA; Hamill RJ; Graybill JR; Sobel JD; Johnson PC; Tuazon CU; Kerkering T; Moskovitz BL; Powderly WG; Dismukes WE
    N Engl J Med; 1997 Jul; 337(1):15-21. PubMed ID: 9203426
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Leave no one behind: response to new evidence and guidelines for the management of cryptococcal meningitis in low-income and middle-income countries.
    Loyse A; Burry J; Cohn J; Ford N; Chiller T; Ribeiro I; Koulla-Shiro S; Mghamba J; Ramadhani A; Nyirenda R; Aliyu SH; Wilson D; Le T; Oladele R; Lesikari S; Muzoora C; Kalata N; Temfack E; Mapoure Y; Sini V; Chanda D; Shimwela M; Lakhi S; Ngoma J; Gondwe-Chunda L; Perfect C; Shroufi A; Andrieux-Meyer I; Chan A; Schutz C; Hosseinipour M; Van der Horst C; Klausner JD; Boulware DR; Heyderman R; Lalloo D; Day J; Jarvis JN; Rodrigues M; Jaffar S; Denning D; Migone C; Doherty M; Lortholary O; Dromer F; Stack M; Molloy SF; Bicanic T; van Oosterhout J; Mwaba P; Kanyama C; Kouanfack C; Mfinanga S; Govender N; Harrison TS
    Lancet Infect Dis; 2019 Apr; 19(4):e143-e147. PubMed ID: 30344084
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cryptococcal Meningitis Treatment Strategies Affected by the Explosive Cost of Flucytosine in the United States: A Cost-effectiveness Analysis.
    Merry M; Boulware DR
    Clin Infect Dis; 2016 Jun; 62(12):1564-8. PubMed ID: 27009249
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antifungal Combinations for Treatment of Cryptococcal Meningitis in Africa.
    Molloy SF; Kanyama C; Heyderman RS; Loyse A; Kouanfack C; Chanda D; Mfinanga S; Temfack E; Lakhi S; Lesikari S; Chan AK; Stone N; Kalata N; Karunaharan N; Gaskell K; Peirse M; Ellis J; Chawinga C; Lontsi S; Ndong JG; Bright P; Lupiya D; Chen T; Bradley J; Adams J; van der Horst C; van Oosterhout JJ; Sini V; Mapoure YN; Mwaba P; Bicanic T; Lalloo DG; Wang D; Hosseinipour MC; Lortholary O; Jaffar S; Harrison TS;
    N Engl J Med; 2018 Mar; 378(11):1004-1017. PubMed ID: 29539274
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cryptococcal meningitis in patients with the acquired immunodeficiency syndrome.
    Zeind CS; Cleveland KO; Menon M; Brown JR; Solomon DK
    Pharmacotherapy; 1996; 16(4):547-61. PubMed ID: 8840361
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of acute cryptococcal meningitis in HIV infected adults, with an emphasis on resource-limited settings.
    Sloan D; Dlamini S; Paul N; Dedicoat M
    Cochrane Database Syst Rev; 2008 Oct; (4):CD005647. PubMed ID: 18843697
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-Dose Fluconazole Consolidation Therapy for Cryptococcal Meningitis in Sub-Saharan Africa: Much to Gain, Little to Lose.
    Murphy RA; Hatlen TJ; Moosa MS
    AIDS Res Hum Retroviruses; 2018 May; 34(5):399-403. PubMed ID: 29353491
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiretroviral roll-out, antifungal roll-back: access to treatment for cryptococcal meningitis.
    Bicanic T; Wood R; Bekker LG; Darder M; Meintjes G; Harrison TS
    Lancet Infect Dis; 2005 Sep; 5(9):530-1. PubMed ID: 16122672
    [No Abstract]   [Full Text] [Related]  

  • 13. Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America.
    Saag MS; Graybill RJ; Larsen RA; Pappas PG; Perfect JR; Powderly WG; Sobel JD; Dismukes WE
    Clin Infect Dis; 2000 Apr; 30(4):710-8. PubMed ID: 10770733
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single-Dose Liposomal Amphotericin B Treatment for Cryptococcal Meningitis.
    Jarvis JN; Lawrence DS; Meya DB; Kagimu E; Kasibante J; Mpoza E; Rutakingirwa MK; Ssebambulidde K; Tugume L; Rhein J; Boulware DR; Mwandumba HC; Moyo M; Mzinganjira H; Kanyama C; Hosseinipour MC; Chawinga C; Meintjes G; Schutz C; Comins K; Singh A; Muzoora C; Jjunju S; Nuwagira E; Mosepele M; Leeme T; Siamisang K; Ndhlovu CE; Hlupeni A; Mutata C; van Widenfelt E; Chen T; Wang D; Hope W; Boyer-Chammard T; Loyse A; Molloy SF; Youssouf N; Lortholary O; Lalloo DG; Jaffar S; Harrison TS;
    N Engl J Med; 2022 Mar; 386(12):1109-1120. PubMed ID: 35320642
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preventing deaths from cryptococcal meningitis: from bench to bedside.
    Roy M; Chiller T
    Expert Rev Anti Infect Ther; 2011 Sep; 9(9):715-7. PubMed ID: 21905781
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness analysis of flucytosine as induction therapy in the treatment of cryptococcal meningitis in HIV-infected adults in South Africa.
    Miot J; Leong T; Takuva S; Parrish A; Dawood H
    BMC Health Serv Res; 2021 Apr; 21(1):305. PubMed ID: 33823842
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fluconazole alone or combined with flucytosine for the treatment of AIDS-associated cryptococcal meningitis.
    Milefchik E; Leal MA; Haubrich R; Bozzette SA; Tilles JG; Leedom JM; McCutchan JA; Larsen RA
    Med Mycol; 2008 Jun; 46(4):393-5. PubMed ID: 18415850
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of cryptococcal meningitis.
    Larsen RA
    N Engl J Med; 1997 Nov; 337(21):1557; author reply 1557-8. PubMed ID: 9380127
    [No Abstract]   [Full Text] [Related]  

  • 19. Amphotericin B with or without flucytosine followed by fluconazole as primary therapy for cryptococcal meningitis in patients with AIDS.
    Jaruratanasirikul S
    Southeast Asian J Trop Med Public Health; 1996 Dec; 27(4):719-23. PubMed ID: 9253873
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The efficacy of sequential treatment with amphotericin B-fluorocytosine and fluconazole in cryptococcal meningitis not associated with AIDS].
    Pintado García V; Martín Dávila P; Muñoz Labián V; Quereda Rodríguez-Navarro C
    Rev Clin Esp; 1999 Jul; 199(7):480. PubMed ID: 10481571
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 19.